<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798003</url>
  </required_header>
  <id_info>
    <org_study_id>NL54799.068.15</org_study_id>
    <nct_id>NCT02798003</nct_id>
  </id_info>
  <brief_title>Food Reward in Cachexia Induced by Acute or Chronic Disease</brief_title>
  <official_title>Analysis of Food Reward System in Cachexia Induced by Acute or Chronic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study activity in the reward-circuitry of the brain in patients suffering from cachexia&#xD;
      induced by cancer or chronic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The activity in the food reward-circuitry of the brain in patients suffering from cachexia&#xD;
      induced by cancer (lung cancer or pancreatic cancer) or chronic disease (chronic obstructive&#xD;
      pulmonary disease) will be analysed by using functional magnetic resonance imaging. In&#xD;
      addition, the role of the peripheral satiety hormones will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reward-related activity in response to food cues, as indicated by Blood Oxygenation Level Dependent (BOLD) values in specified brain areas related to food reward.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary intake assessed by a food diary</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters: glucose (mmol/L)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters: insulin (pmol/L)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters: leptin (ug/L)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters: ghrelin (pg/mL)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters: glucagon-like peptide-1 (pmol/L)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Anthropometrical characteristics: body mass index (kg/m2)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other relevant co-variables: current medical status (charlson co-morbidity index scale)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other relevant co-variables: World Health Organization performance score (WHO PS)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other relevant co-variables: pulmonary function (Forced Expiration Volume in 1 second [FEV1] in % predicted)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other relevant co-variables: pulmonary function (diffusing capacity of the lungs for carbon monoxide [DLCO] in % predicted)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other relevant co-variables: weight change past 6 months (kg)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other relevant co-variables: self-reported smoking status of all 44 participants (current, former, never, in pack years)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in food preferences assessed by the Functional Assessment of Anorexia/Cachexia Therapy (FAACT)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive functioning assessed by Mini-Mental State Examination (MMSE)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive functioning assessed by Cognitive Failure Questionnaire (CFQ)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of depression and anxiety assessed by the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>General wellbeing assessed by the European Organization for Research and Treatment of Cancer (EORTC) c30 questionnaire</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory parameters: c-reactive protein (ml/L)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Cachexia</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cachectic cancer patients</arm_group_label>
    <description>Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-cachectic cancer patients</arm_group_label>
    <description>Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cachectic COPD patients</arm_group_label>
    <description>Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-cachectic COPD patients</arm_group_label>
    <description>Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional magnetic resonance imaging (fMRI)</intervention_name>
    <description>The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.</description>
    <arm_group_label>Cachectic COPD patients</arm_group_label>
    <arm_group_label>Cachectic cancer patients</arm_group_label>
    <arm_group_label>Non-cachectic COPD patients</arm_group_label>
    <arm_group_label>Non-cachectic cancer patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Four groups will be included:&#xD;
&#xD;
          1. Cachectic cancer patients, including NSCLC and gastro-intestinal cancer&#xD;
&#xD;
          2. Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer&#xD;
&#xD;
          3. Cachectic COPD patients&#xD;
&#xD;
          4. Non-cachectic COPD patients&#xD;
&#xD;
        Individuals of all groups will be gender and age matched. In addition, COPD patients will&#xD;
        be matched for FEV1.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For cachectic patients: weight loss exceeds 5% of total body weight over the past 6&#xD;
             months, or &gt;2% when body mass index is &lt;20 kg/m2&#xD;
&#xD;
          -  For non-cachectic patients: no weight loss of â‰¥5% during the last 6 months&#xD;
&#xD;
          -  Non-small cell lung cancer or gastro-intestinal cancer, pathology proven or diagnosis&#xD;
             of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease&#xD;
             (GOLD) criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indications for fMRI examination (operation to your head or brain in the past;&#xD;
             implanted electronic devices, for instance a pacemaker, neurostimulator, cochlear or&#xD;
             hearing implant; insulin pump under your skin; Pregnant subjects, claustrophobia;&#xD;
             pregnancy; metal parts in your body (except from teeth filling and connectors):&#xD;
             implants; brain vessel clamps, prostheses, intra-uterine device, metal splinter in the&#xD;
             eye, metal braces or other metal objects, permanent eye make-up)&#xD;
&#xD;
          -  Psychiatric or other disorders likely to impact on informed consent&#xD;
&#xD;
          -  Presence of brain metastasis (screening is not mandatory)&#xD;
&#xD;
          -  Medical history of cerebrovascular accident, brain tumour, brain metastasis&#xD;
&#xD;
          -  Previous radiotherapy to brain, both stereotactic and whole brain radiotherapy&#xD;
&#xD;
          -  Memory problems&#xD;
&#xD;
          -  Current use of tube feeding or parental nutrition&#xD;
&#xD;
          -  Patients with an active second malignancy&#xD;
&#xD;
          -  Patients unable to lie still for 2 hours&#xD;
&#xD;
          -  Unable to complete the cognitive task&#xD;
&#xD;
          -  Pre-existing swallowing difficulties&#xD;
&#xD;
          -  Allergy to gluten-, milk- or wheat products&#xD;
&#xD;
          -  Self-reported hyperthyroidism&#xD;
&#xD;
          -  Self-reported diabetes mellitus&#xD;
&#xD;
          -  Current use of appetite stimulant medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annemie Schols, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Sanders, MD</last_name>
    <phone>0031433884597</phone>
    <email>k.sanders@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith de Vos-Geelen, MD</last_name>
    <phone>0031433872001</phone>
    <email>judith.de.vos@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Sanders, MD</last_name>
      <phone>0031433884597</phone>
      <email>k.sanders@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cachexia</keyword>
  <keyword>Food reward</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

